FLT3 and acute myeloid leukemia: A phase 2 study demonstrated the potency and efficacy of Quizartinib amongst FLT3+ R/R AML patients within 1 year of induction therapy, or who had undergone salvage chemotherapy, or allo-HSCT [47, 48].